Bausch + Lomb said on Thursday its glaucoma eye drop had missed ​the main goal in a mid-stage ‌trial of replicating visual function improvements observed in a smaller study.

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating ...

Glaucoma is the leading cause of irreversible visual impairment worldwide. Because the disease often progresses without ...

From memorable patient encounters to emerging therapies, OT talks with practitioners about opportunities and challenges in ...

The charity has encouraged optometrists to signpost eligible patients living with, or being monitored for, glaucoma to the ...

I heard Wayne had to give up driving because he is blind from glaucoma, but I saw him at the cafe reading a newspaper. I’m struggling to make sense of that: what is glaucoma?” ...

Glaucoma can silently damage vision but everyday habits may influence its progression. Learn seven common mistakes patients ...

Halos Around Lights at Night You notice a coloured ring around a streetlight or an oncoming headlight and assume your eyes ...

Glaucoma is often called the "silent thief of sight" because it usually develops without pain or noticeable symptoms until permanent vision loss has already occurred. Eye specialists warn that regular ...

It plays a significant role in the development of conditions that can lead to blindness. But most of these can be prevented ...